ClinicalTrials.gg
Active, not recruitingNCT03255915PrEP-Pod-IVRUpdated Aug 26, 2026

PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

An Early Phase 1 interventional study of Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) and Placebo in HIV Prevention, sponsored by Oak Crest Institute of Science. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Oak Crest Institute of Science · Early Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Participants will have a 28-day pre-ring baseline assessment period (Stage 1) followed by randomization to order with 5 participants per study arm. All participants will sequentially receive both study products for 28-days with at least a 2-week washout period between products. Arm 1 will receive the TDF-FTC pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3. Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the TDF-FTC pod-IVR during Stage 3. During Stages 2 \& 3 participants will also complete brief phone surveys (\<3 min), computer-assisted self-interviews (CASIs), and in-depth interviews (IDIs) regarding perceptibility and acceptability. If willing, participants' male sexual partners will be invited to complete IDIs as well.

02

Conditions studied

  • HIV Prevention

Keywords

  • HIV Prevention
  • Intravaginal Ring
  • Tenofovir Disoproxil Fumarate
  • Emtricitabine
03

In context

Lead sponsor

This is the only study on the registry with Oak Crest Institute of Science as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18 through 45 years at screening, verified per site SOP
  2. Female participants, born female
  3. Not pregnant or breastfeeding
  4. Availability to return for all study visits, barring unforeseen circumstances
  5. Willing and able to

    • communicate in English
    • provide written to take part in the study
    • provide adequate locator information, as defined in site SOP
    • complete all required study procedures, including phone surveys, daily vaginal swabs, and reliably store swabs in freezer
  6. Must agree

    • not to participate in other concurrent interventional and/or drug trials
    • to use study-provided condoms for vaginal or anal intercourse for the duration of the study
    • to abstain from use of any vaginal products (e.g., lubricants, feminine hygiene products, vaginally administered products, sex toys) other than study products for the duration of the study beginning at enrollment Note: Tampons may be used during menses, but must be discontinued 72 hours prior to study visits and for 7 days after procedures. Menstrual pads will be provided to participants.
    • to abstain from receptive oral, vaginal, or anal intercourse during the first week after each pod-IVR insertion and for 2 days before and 7 days after biopsy procedures
    • to abstain from insertion of anything in the vagina (e.g., tampon, finger, sex toy, lubricants, medication, douche) during the first week after each pod-IVR insertion and for 2 days before and 7 days after biopsy procedures
  7. Understands and agrees to local STI reporting requirements
  8. -1 seronegative at screening
  9. Must be in general good health in the opinion of the investigator
  10. Regular menstrual cycles of approximately 21 to 35 days apart with no untreated intermenstrual menstrual bleeding Note: This criterion is not applicable to participants using continuous combination oral contraceptive pills or progestin-only methods (such as Depo-Provera or levonorgestrel-releasing IUD), as the absence of regular menstrual cycles is an expected, normal consequence in this context.
  11. Satisfactory cervical Pap result in the 36 calendar months prior to Enrollment consistent with Grade 0 according to the Female Genital Grading Table for Use in Microbicide Studies [Addendum 1, Dated November 2007], or if Grade 1 or higher Pap result has had a satisfactory evaluation with no treatment required per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines in the 12 calendar months prior to Enrollment
  12. Using an effective method of contraception and intending to continue use of an effective method for the duration of study participation. Acceptable methods include:

    • hormonal methods (except contraceptive vaginal rings)
    • IUD
    • sterilization of participant or partner

    In addition to the criteria listed above, participants who agree to have rectal biopsies collected must meet the following criteria:

  13. Must agree to abstain from insertion of anything in the rectum (e.g., finger, sex toy, lubricants, medication, enema) during the first week after each pod-IVR insertion and for 2 days before and 7 days after biopsy procedures

Male sexual partner(s) who meet the following criteria are eligible for inclusion in the study:

  1. Age of 18 years or over
  2. Has a female sexual partner enrolled in the study
  3. Willing and able to

    • communicate in English
    • provide written informed consent to take part in the study
    • provide adequate locator information, as defined in site SOP
    • complete in-depth interview via video conference

Exclusion criteria

Exclusion Criteria:

Individuals who meet any of the following criteria will be excluded from the study:

  1. Undergoing or completed gender reassignment
  2. Participant reports any of the following at Screening:

    1. Has plans to relocate away from the study site area during the period of study participation
    2. Pregnant, less than 3 months post-partum, or lactating
    3. Intends to become pregnant during the period of study participation
    4. Current or planned use of an IVR
    5. Known -infected partners
    6. Non-therapeutic injection drug use in the 6 months prior to screening
    7. History of disease
    8. History of toxic shock syndrome
    9. History of adverse reaction to TDF, FTC, silicone, or microcrystalline cellulose
    10. PrEP or Post-exposure prophylaxis for HIV exposure within 6 months prior to screening
    11. Use of systemic immunomodulatory medications within the 4 weeks prior to the Enrollment
    12. Use of vaginally or rectally administered medications or products (including condoms) containing Nonoxynol-9 (N-9) within the 4 weeks prior to the Enrollment
    13. Participating in another research study involving drugs or medical devices within the 4 weeks or 5 half-lives (if known) prior to the Enrollment
    14. Gynecologic or genital procedure (e.g., tubal ligation, dilation and curettage, piercing) within 60 days prior to Enrollment

    Note: Colposcopy and cervical for evaluation of an abnormal Pap smear as well as IUD removal are not exclusionary

  3. Per participant report at screening, anticipated use and/or unwillingness to abstain from the following medications during the period of study participation:

    1. Heparin, including Lovenox® (enoxaparin sodium)
    2. Warfarin
    3. Plavix® (clopidogrel bisulfate)
    4. Any other drugs that are associated with increased likelihood of bleeding following mucosal biopsy (e.g., daily high dose aspirin, Pradaxa®)
    5. NSAID use for 5 half-lives prior to biopsy (e.g. ibuprofen for 1 day, naproxen for 4 days).
    6. Rectally or vaginally administered medications (including over-the-counter products)
  4. History of significant gastrointestinal bleeding in the opinion of the investigator
  5. Abnormalities of the cervical, vaginal, or colorectal mucosa, or significant symptom(s), which in the opinion of the clinician represents a to protocol-required biopsies (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids). Erythema is not exclusionary.

    • Includes any clinically apparent Grade 2 or higher pelvic examination finding (observed by study staff) at Screening or Enrollment, as per the Female Genital Grading Table for Use in Microbicide Studies [Addendum 1, Dated November 2007]
  6. At screening: participant-reported symptoms and/or clinical or laboratory diagnosis of active rectal or reproductive tract infection requiring treatment per current CDC guidelines or symptomatic urinary tract infection (UTI). Infections requiring treatment include symptomatic bacterial vaginosis, symptomatic vaginal candidiasis, trichomoniasis, chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, pelvic inflammatory disease, genital sores or ulcers, cervicitis, or symptomatic genital warts requiring treatment (i.e., those that cause undue burden or discomfort to the participant).

    Note:

    • An HSV-1 or HSV-2 seropositive diagnosis with no active lesions is allowed, since treatment is not required
    • One re-screening after documented treatment will be allowed
  7. Has any of the following laboratory abnormalities at Screening:

    Note: Grade is per Version 2.1 of the DAIDS Toxicity Table

    1. Grade 1 or higher
    2. count Grade 1 or higher
    3. (INR) Grade 2 or higher
    4. White blood cell count Grade 2 or higher
    5. Calculated ≤ 80 mL/minute using the Cockcroft-Gault equation
    6. Grade 2 or higher and/or AST (i.e., ≥ 2.5x the site laboratory [ULN])
    7. Positive for surface antigen (HBsAg)
    8. Positive for antibody (HCV Ab)
  8. Has any other condition that, in the opinion of the Principal Investigator or designee, would preclude , make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives

Male sexual partner(s) who meet the following criteria are not eligible for inclusion in the study:

1) Female partner did not utilize study product

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Arm 1

    Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.

    Drug: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) · Other: Placebo

  • Experimental
    Arm 2

    Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.

    Drug: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of Vaginal IVRs releasing TDF-FTC by reports of Adverse Events

    Adverse events Grade 2 or higher as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, March 2017, Addendum 1 Female Genital Grading Tables for Use in Microbicide Studies (November 2007), and/or Addendum 3 Rectal Grading Table for Use in Microbicide Studies (Clarification dated May 2012) to this table

    Time frame: From date of enrollment until the date of study completion or date of study withdrawal from any cause, whichever came first, assessed up to 6 months

  2. Characterization of pharmacokinetics of TDF-FTC released by an IVR - plasma

    To characterize the local and systemic pharmacokinetics (PK) of TDF-FTC delivered via a pod-IVR, including drug concentration in plasma.

    Time frame: From date of enrollment until the date of study completion or date of study withdrawal from any cause, whichever came first, assessed up to 6 months

  3. Characterization of pharmacokinetics of TDF-FTC released by an IVR - vagina

    To characterize the local and systemic pharmacokinetics (PK) of TDF-FTC delivered via a pod-IVR, including drug concentration in vaginal secretions and tissue.

    Time frame: From date of enrollment until the date of study completion or date of study withdrawal from any cause, whichever came first, assessed up to 6 months

  4. Characterization of pharmacokinetics of TDF-FTC released by an IVR - rectum

    To characterize the local and systemic pharmacokinetics (PK) of TDF-FTC delivered via a pod-IVR, including drug concentration in rectal secretions.

    Time frame: From date of enrollment until the date of study completion or date of study withdrawal from any cause, whichever came first, assessed up to 6 months

Secondary outcomes

  1. Acceptability of IVR assessed via computer assisted self interviews

    Self-reported attitudes of participants about experience and product attributes via computer assisted self interviews

    Time frame: 28 days after use of each IVR

  2. Acceptability of IVR assessed via in depth interviews

    Self-reported attitudes of participants about experience and product attributes via in depth interviews

    Time frame: 28 days after use of each IVR

  3. Adherence

    Measured by vaginal fluid PK drug levels, vaginal tissue PK drug and drug metabolite levels, and residual drug levels in returned, used pod-IVRs.

    Time frame: From date of IVR insertion until the date of IVR removal or date of study withdrawal from any cause, whichever came first, assessed up to 6 months

  4. Acceptability of IVR assessed via in depth interviews - male partners

    Self-reported attitudes of participant's male sexual partner(s) about experience and product attributes via in-depth interviews.

    Time frame: 28 days after subject use of each IVR

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Sep 2020, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2017
First posted
Aug 21, 2017
StartActual
Sep 20, 2018
Primary completionActual
Sep 30, 2020
CompletionEst.
Dec 31, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03255915
Lead sponsor
Oak Crest Institute of Science
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Sep 20, 2018
Primary completion
Sep 30, 2020
Completion
Dec 31, 2026 (estimated)
Last update
Aug 26, 2026

Study contacts

Kathleen L Vincent, MD
principal investigator · University of Texas

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion